Why do we need a Public-Private partnership?
Giving patients a voice in drug development
What is a patient preference?
Whose preferences are we collecting?
News from the PREFER project
- PARADIGM reports from PREFER annual meeting: Understanding patient preferences – the next frontier in PE 2019-11-04
- Right now in Basel: PREFER annual meeting 2019 2019-10-21
- Want a summary of what we have published? 2019-10-16
- Critical need for better methodological understanding of preference methods 2019-10-07
- Live webinar on patient preferences in European HTA 2019-09-30
Clinical case studies
We have started three core PREFER patient preference studies looking at cancer, rheumatoid arthritis and neuromuscular disorders. Both academic and industry partners are adding more patient preference studies to the PREFER portfolio that will help us cover different disease areas, methods and research questions.
Want to stay updated on what is going on in PREFER? Follow us on Twitter and YouTube, or subscribe to our newsletter!
We are developing evidence-based recommendations to guide industry, regulatory authorities, HTA bodies, reimbursement agencies, and health care professionals. We start with work to assess methodologies. After that, we test them in clinical case studies. This work will be the basis for the recommendations we make.
Together with stakeholders
PREFER is a public-private partnership with collaboration at every level, making sure we get more than one perspective on everything we do. We have stakeholder partners from Health Technology Assessment bodies and patient organisations. We are also working closely with regulators to ensure recommendations are evidence based, relevant and useful.
Finding out what patients prefer
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when, and how patients’ treatment preferences can be used in medical product development.
We are looking forward to sharing our findings with you!
Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader
Innovative Medicines Initiative
PREFER is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme.
The academic research in PREFER is funded by Horizon 2020: the EU Framework Programme for Research and Innovation.
The pharmaceutical industry contributes equally to the PREFER project. Industry input to the IMI programme is organised by EFPIA.